eligibility_summary
Eligible: adults 18–70 with recurrent/metastatic HNSCC not curable, prior RT >6 mo, no prior systemic chemo except curative multimodal ≥6 mo ago, ECOG 0–1, measurable disease, adequate marrow/liver/renal. Exclude: severe mAb allergy, prior camrelizumab or cetuximab (unless curative-intent), serious heart disease/QTc>500, recent major surgery, active autoimmune, uncontrolled comorbid/lung disease, CNS disease, active HBV/HCV/HIV/immunodef, pregnancy/lactation, infection, neuro/psych illness, drug abuse.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm trial in relapsed/metastatic HNSCC tests: 1) Camrelizumab—humanized IgG4 anti‑PD‑1 immune checkpoint inhibitor, blocks PD‑1 on T cells to restore antitumor cytotoxicity. 2) Cetuximab—chimeric IgG1 anti‑EGFR monoclonal antibody, inhibits EGFR signaling (RAS/RAF/MEK/ERK, PI3K/AKT) and elicits ADCC via NK cells/macrophages. 3) Nab‑paclitaxel—albumin‑bound taxane cytotoxic, stabilizes microtubules causing mitotic arrest. 4) Cisplatin—platinum cytotoxic, creates DNA crosslinks inducing apoptosis. Targets/pathways: PD‑1/PD‑L1 axis on activated T cells, EGFR on tumor cells, microtubules in proliferating cells, DNA replication/repair, Fcγ receptor–mediated ADCC. Chemo may enhance antigen release and responsiveness to PD‑1 blockade.